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HIGHLIGHTS 
 
 A screening of combinations with EGCG is carried out with the MTT assay. 
 EGCG synergistically interact with 4-methylumbelliferone. 
 EGCG is an antagonist of the antiproliferative effects of vitamin D3. 
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Summary 
Purpose: To screen for possible synergistic interactions of epigallocatechin-3-gallate 
(EGCG) with a selection of 10 anti-angiogenic or anti-tumor compounds on the survival 
of endothelial and tumor cells. 
Methods: Human HMEC endothelial and MDA-MB231 breast cancer cells were treated 
with different concentrations of EGCG and the 10 tested compounds either as single 
agents or in paired combinations with EGCG for 3 days and final survival of cells was 
determined by the MTT assay. IC50 values, sensitization factors and combination 
indexes were calculated. 
Results; IC50 values of 140±2 and 45±6 µM were determined for EGCG-treated 
endothelial and tumor cells, respectively. IC50 values for all tested compounds were 
within the micromolar and the submillimolar range. The values of the sensitization 
factor increased and those of the combination index decreased for paired combinations 
of EGCG with 4-methylumbelliferone. The opposite was true for the combination of 
EGCG with vitamin D3. Other tested combinations did not exhibit a clear monotonic 
effect but rather a biphasic behaviour. 
Conclusion: Combinations of EGCG and 4-methylumbelliferone synergistically 
decrease endothelial and tumor cell survival. In contrast, the presence of EGCG 
antagonizes with the antiproliferative effect exerted by vitamin D3 on endothelial and 
tumor cells. 
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1. Introduction 
 
Solid cancers have several common characteristics that Hanahan & Weinberg named as 
the hallmarks of cancer [1]. Angiogenesis is an essential hallmark of cancer because 
tumor cells need oxygen and nutrients delivered by the vascular system [2]. In fact, 
tumor growth and metastasis are angiogenesis dependent processes, and microvascular 
endothelial cells recruited by tumors have become an important target in cancer therapy 
[1-3]. 
Drug discovery efforts have identified several potential therapeutic targets in 
endothelial cells and selective inhibitors capable of slowing tumor growth or producing 
tumor regression by blocking angiogenesis in in vivo tumor models [4]. However, the 
currently available therapies have limited success in patients, due to complex 
mechanisms of resistance of the tumor cells [5,6]. One approach to overcoming these 
problems is to use combinations of drugs with different modes of action that may lead 
to enhanced antitumor and antiangiogenic effects without injuring the host [5-7]. The 
combined use of two drugs may sometimes produce enhanced, unchanged or 
diminished effects in comparison with their individual effects. These three different 
types of behaviour of the interacting drugs are called synergy, additive/indifferent and 
antagonistic effects [8]. 
Our research group is devoted to the screening, identification and characterization of 
new modulators of angiogenesis. In the last years we have identified a number of 
natural compounds as new inhibitors of angiogenesis [see for instance 9-14]. We have 
also claimed for the need of combinatorial approaches to manage angiogenesis [5]. 
Epigallocatechin-3-gallate (EGCG) is an abundant polyphenol in green tea leaves with a 
number of biological activities, including antiangiogenesis [5], anticarcinogenesis [16-
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18], antimetastasis [19], as well as cancer chemoprevention, among others [20]. 
Furthermore, our group has previously shown that EGCG is a potent antiinflammatory 
compound [21,22] targeting histidine decarboxylase [23-25].  
In the present work, we analyze paired combinations of EGCG with other 10 bioactive 
compounds (see Table 1), some described by our research group as potent 
antiangiogenic compounds, and others currently used in clinical therapy [11-14, 26-32].  
 
2. Material and methods 
 
2.1. Materials 
Metformin, leflunomide, TNP-470, sunitinib malate, kahweol, cholecalciferol (vitamin 
D3), 4-methylumbelliferone, dimethyl fumarate, Paclitaxel and epigallocatechin-3-
gallate were purchased from Sigma Chemicals Co. (St. Louis MO, USA). 
Hydroxytyrosol was supplied by Extrasynthèse (Lyon, France). Supplements and other 
chemicals not listed in this section were obtained from Sigma Chemicals Co. (St. Louis 
MO, USA). Cell culture media, penicillin, streptomycin and amphotericin B were 
purchased from Biowhittaker (Walkersville, MD, USA). Fetal bovine serum (FBS) and 
human serum (HS) were products of Harlan-Seralab (Belton, United Kindom). Plastics 
for cell culture were supplied by NUNC (Roskilde, Denmark) and VWR (West Chester, 
Pennsylvania, USA). 
 
2.2. Cell culture 
The immortalized human microvascular endothelial cell (HMEC) line was kindly 
supplied by Dr. Arjan W. Griffioen (Maastrich University, The Netherlands). This 
immortalized cell line has been previously characterized [33]. HMEC cells were grown 
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in RPMI 1640 medium supplemented with glutamine (2mM), penicillin (50 IU/mL), 
streptomycin (0.05 mg/mL), and amphotericin (1.25 mg/L) supplemented with 10% 
fetal bovine serum, and 10% human serum. Human breast cancer carcinoma MDA-MB-
231 cells were purchased from ATCC and maintained in RPMI 1640 supplemented with 
glutamine (2mM), penicillin (50 IU/mL), streptomycin (0.05 mg/mL), and amphotericin 
(1.25 mg/L) supplemented with 10% fetal bovine serum. Cell cultures were maintained 
at 37°C under a humidified 5% CO2 atmosphere. 
 
2.3. MTT cell growth assay 
The 3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide (MTT) dye 
reduction assay in 96-well microplates was used. The assay is dependent on the 
reduction of MTT by mitochondrial dehydrogenases of viable cells to a blue formazan 
product, which can be measured spectrophotometrically. Tumor cells (2.5x10
3 
cells in a 
total volumen of 100 μL of complete medium) were incubated in each well with serial 
dilutions of single compounds or with paired combinations. After 3 days of incubation 
in the dark (37°C, 5% CO2 in a humid atmosphere), 10 μL of MTT (5mg/mL in PBS) 
was added to each well, and the plate was incubated for a further 4 h (37°C). The 
formazan was solved in 150 μM of 0.04 N HCl-2 propanol, and samples were 
spectrophotometrically measured at 550 nm. All determinations were carried out in 
quadruplicate, and at least three independent experiments were carried out. IC50 values 
were calculated as those concentrations of compound yielding 50% of cell survival, 
taking the values obtained for control as 100%. Firstly, we calculated IC50 values for 
each single compound on both cell lines. Once we knew these values for single 
compounds, we performed the different combinations of EGCG with the 10 selected 
compounds (Table 1) at concentrations from 4xIC50 to 1/8 IC50.  
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From these experiments, the effect of paired combinations was evaluated with two 
different approaches: determination of combination indexes and sensitization factors 
(see sections 2.4 and 2.5). 
 
2.4. Combination index (CI) 
The so-called combination index (CI) is defined as: CI = [Ca/ICa] + [Cb/ICb],  where 
Ca an Cb are the concentrations of compounds A and B used together to achieve a fixed 
effect. ICa and ICb are the concentrations of A and B, respectively required individually 
to achieve the same effect [8]. Here, we have used as a fixed effect that corresponding 
to IC50. A CI value of less than, equal to, and more than one, indicates synergy, 
additivity and antagonism, respectively, between these two compounds. 
 
2.5. Sensitization factors 
The sensitization factors indicate he degree of sensitization induced by EGCG on the 
effects of the 10 selected compounds on cell survival. They were calculated as the ratio 
of IC50 (control cells)/ IC50 (EGCG treated cells). 
 
 
3. Results 
 
3.1. Studies of cell growth and survival with single compounds 
Figure 1 shows the survival curves (determined with the MTT assay) of both HMEC 
endothelial and MDA-MB231 tumor cells treated with EGCG. From these survival 
curves IC50 values of 140±2 and 45±6 µM were determined for endothelial and tumor 
cells, respectively. Following the same procedure, the dose-response histograms 
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(Figures 2 and 3) and IC50 values (Tables 2-3) were obtained for both HMEC 
endothelial and MDA-MB231 tumor cells treated with each of the 10 selected single 
compounds. All IC50 values were within the micromolar and the submillimolar range. 
For both HMEC endothelial and MDA-MB231 tumor cells, the lowest IC50 values are 
obtained with Paclitaxel (0.7±0.0 and 1.1±0.2 µM, respectively) and the highest ones 
with 3-methylumbelliferone (651.8 ± 38.5 and 626.7 ± 204.9 µM, respectively). No 
relevant cell specificity was found, with the notable exception of  vitamin D3, a 
compound that exhibited a much higher toxicity for MDA-MB231 tumor cells 
(IC50=33.7 ± 3.0 µM) than for HMEC endothelial cells (IC50=331.5±6.2 µM).   
 
3.2. Sensitivity of HMEC to the selected compounds in the presence of EGCG 
Figure 2 and Table 2 show the effects of exposure schedules of EGCG on HMEC 
endothelial cells treated with each of the 10 selected test compounds (Table 1). Changes 
in the IC50 (Table 2) values at the different EGCG concentrations tested are displayed 
along with the corresponding sensitization factor values calculated as described in 
Material and methods. As observed in this table, the values of the sensitization factor 
were higher than 1 and they increased with increasing EGCG concentrations in the 
cases of 4-methylumbelliferone, dimethylfumarate, Paclitaxel and sunitinib. There 
seemed to be a biphasic behaviour (with sensitization factor values lower than 1 at 
lower EGCG concentrations and higher than 1 at the highest tested EGCG 
concentrations) in the cases of hydroxytyrosol, leflunomide, metformin and TNP-470. 
However, with the exception of leflunomide, the pro-sensitizating effect of EGCG was 
only observed at 560 µM EGCG, with values below 1 for the rest of tested EGCG 
concentrations. Finally, it is noteworthy the very strong anti-sensitizating effect of 
EGCG in vitamin D3-treated HMEC endothelial cells. 
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3.3. Sensitivity of MDA-MB231 breast cancer cells to the selected compounds in 
the presence of EGCG 
Figure 3 and Table 3 show the effects of exposure schedules of EGCG on MDA-
MB231 tumor cells treated with each of the 10 selected test compounds (Table 1). 
Changes in the IC50 (Table 3) values at the different EGCG concentrations tested are 
displayed along with the corresponding sensitization factor values calculated as 
described in Material and methods. In contrast with the data obtained for HMEC 
endothelial cells, in the case of MDA-MB231 tumor cells EGCG treatment gave rise to 
a biphasic behaviour for most of the treatments, with anti-sensitizating effects at lower 
concentrations and pro-sensitizating effects at higher concentrations of EGCG. 
 
 
3.4. Combination indexes of EGCG in combination with the 10 selected test 
compounds 
Table 4 shows the CI values obtained for paired combinations of EGCG and each of the 
10 selected compounds in both HMEC endothelial and MDA-MB231 tumor cells. 
Synergistic effects are only observed for the combinations of EGCG with 4-
methylumbelliferone and Paclitaxel in HMEC endothelial cells and EGCG with 4-
methylumbelliferone in MDA-MB231 tumor cells. For most of the combinations CI 
values higher than 1 are shown, indicating an antagonistic effect of EGCG on the 
treatments. The most relevant antagonistic effect seems to be that of the combination of 
EGCG with vitamin D3.  
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4. Discussion 
In the last years the convenience of combinatory approaches yielding synergistic 
antitumoral and antiangiogenic effects are more and more claimed [5,7]. EGCG is a 
natural compound with a wide array of biological activities. In fact, EGCG has been 
shown to have antitumor, antiangiogenic and antiinflammatory effects [15-25]. This 
makes EGCG a potentially interesting candidate for screening studies searching for 
synergistic combinations.  
Some previous studies have analyzed the effects of combinations of EGCG with several 
compounds. For instance, EGCG nanoparticles enhance the cancer chemosensitization 
potential of cisplatin [34]. Combinations of EGCG with IL-1R antagonist are effective 
downregulating IL-1-induced tumorigenic factors in U-2 OS human osteosarcoma cells 
[35]. Another combination with positive inhibitory effects is that of EGCG combined 
with capecitabine, which inhibits angiogenesis and tumor growth in nude mice with 
gastric cancer xenografts [36]. Some combinations of EGCG have been reported to 
induce antagonistic effects. Thus, EGCG has been shown to inhibit IGF-I-stimulated 
lung cancer angiogenesis and nicotine-induced migration and invasion of non-small cell 
lung cancer cells [37,38]. On the other hand, there are some few studies reporting 
synergistic interactions of EGCG with other compounds. EGCG has been reported to 
sensitize human prostate cancer cells to TRAIL-mediated apoptosis, both treatments 
synergistically inhibiting angiogenesis and metastasis associated biomarkers [39]. 
Another study demonstrated that curcumin synergizes with EGCG when administered 
in a sequential fashion overcoming stromal protection of chronic lymphocytic leukemia 
B cells [40]. EGCG and Vorinostat exhibit synergistic anticancer effects against human 
cholangiocarcinoma cells [41]. 
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For the screening of potential synergistic interactions of EGCG combined with other 
compounds, we decided to use as a first approach the analysis of the effects of 
endothelial and tumor cell survival as determined by the MTT assay, a simple, rapid and 
inexpensive procedure widely used for screening purposes. The list of 10 selected 
compounds for screening of their paired combinations with EGCG (Table 1) includes 4 
natural compounds previously described as antiangionenic agents by our group, namely, 
4-methylumbelliferone [14], dimethyl fumarate [11], hydroxytyrosol [13] and kahweol 
[12]. The list includes other two antiangiogenic compounds (leflunomide and TNP-470) 
and four antitumoral compounds (metformin, Paclitaxel, sunitinib and vitamin D3). 
Paclitaxel and sunitinib are currently used in the clinic. Paclitaxel is currently used for 
the treatment of several kinds of cancer, including breast, ovarian and lung cancer [26]. 
Sunitinib has been described as an antitumoral agent by its potent inhibition of the 
phosphorylation of tyrosin kinases and was approved in 2006 by FDA as an 
antiangiogenic therapy [27]. TNP-470 is an antiangiogenic compound with a very 
strong inhibitory effect on endothelial cell proliferation [28]. Leflunomide is an 
immunomodulatory drug inhibiting mitochondrial enzyme dihydrorotate 
dehydrogenase, which plays a key role in the de novo synthesis of the pyrimidine 
ribonucleotide uridine monophosphate (rUMP) [29]. Metformin is a compound used in 
diabetes treatment and as antitumoral because it interferes with the mTOR pathway 
[30,31]. The beneficial role of the vitamin D3 in suppressing inflammation with 
subsequent colon cancer prevention is well documented [32]. 
Although in the present study we have made use only of the IC50 values, sensitization 
factors and combination indexes, other parameters potentially useful can be determined 
from the experimental data obtained with such a kind of screening. For instance, IC90 
values are calculated as those concentrations of compound yielding 10% of cell 
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survival, taking the values obtained for control as 100%. Taking altogether the set of 
results shown in Figures 2 and 3 and Tables 2-4, most of the tested combinations do not 
yield synergistic effects at all. In fact, only the combination of EGCG with 4-
methylumbelliferone revealed consistent sensitizations and CI values below 1 pointing 
to a synergistic effect of both compounds on both endothelial and tumor cell survival. 
Recent published results point to the potential of 4-methylumbelliferone as an effective 
chemopreventive and therapeutic agent based on its proven antiangiogenic and 
antitumor effects [42,43]. In contrast, the strong antagonistic effect of the combination 
of EGCG with vitamin D3 is noteworthy. It seems as if the presence of any of these two 
compounds protects cells from the toxicity of the other compound, leading to an 
increase of the respective, effective IC50 values. An interesting cell-specific case is that 
of Paclitaxel, since EGCG synergizes with it in HMEC endothelial cells and 
antagonizes with it in MDA-MB231 tumor cells. 
 
5. Conclusion 
Data presented here show that, in spite of the wide range of biological effects previously 
demonstrated for EGCG, it does not synergize with most of the ten tested 
antiangiogenic or antitumor compounds. EGCG produces synergistic effects on both 
endothelial and tumor cell survival when combined with 4-methylumbelliferone. On the 
other hand, EGCG behaves as a very strong antagonist of the antiproliferative effects of 
vitamin D3. Therefore, these two combinations deserve to be further analyzed in the 
future with additional pre-clinical assays to test whether these synergistic and 
antagonistic effects on cell survival are companied (or not) by other effects on key steps 
of angiogenesis and other hallmarks of cancer. For instance, potential synergistic effects 
on apoptosis could be tested by carrying out cell cycle analysis by flow cytometry, 
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mitochondrial membrane potential determination, caspase activation assay and poly 
(ADP-ribose) polymerase cleavage determination by Western blotting, among others. 
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Figure legends 
 
Figure 1 Dose-response curves showing the effect of EGCG treatment on HMEC 
endothelial (circles) and MDA-MB231 tumor (squares) cell survival. Data are 
means±SD for three independent experiments (each with 4 replicates of each test point). 
 
Figure 2 HMEC endothelial cell dose-response histograms showing the effect of paired 
compounds. A) 4-MU/EGCG, B) DMF/EGCG, C) HT/EGCG, D) Kahweol/EGCG, E) 
Leflunomide/EGCG, F) Metformin/EGCG, G) Paclitaxel/EGCG, H) Sunitinib/EGCG, 
I) TNP-470/EGCG, J) Vit. D3/EGCG. Data are shown as means±S.D. for 3 independent 
experiments (each with 4 replicates of each test point). 
 
Figure 3 MDA-MB231 tumor cell dose-response histograms showing the effect of 
paired compounds. A) 4-MU/EGCG, B) DMF/EGCG, C) HT/EGCG, D) 
Kahweol/EGCG, E) Leflunomide/EGCG, F) Metformin/EGCG, G) Paclitaxel/EGCG, 
H) Sunitinib/EGCG, I) TNP-470/EGCG, J) Vit. D3/EGCG. Data are shown as 
means±S.D. for 3 independent experiments (each with 4 replicates of each test point). 
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Tables 
This manuscript includes 4 Tables. 
Compound 
Molecular 
structure 
Describe as… Molecular target 
4-methylumbelliferone (4-
MU) 
 
Anti-angiogenic 
Inhibitor of 
hyaluronic acid 
synthesis 
Cholecalciferol 
(Vit D3) 
 
Anti-tumoral 
Inhibitor signalling 
of Wnt pathway 
Dimethylfumarate 
 (DMF) 
 
Anti-angiogenic 
Inhibitor of 
VEGFR-2 
Epigallocatechin gallate 
(EGCG) 
 
Anti-angiogenic 
Inhibitor of 
topoisomerases 
Hydroxytyrosol  
(HT)  
Anti-angiogenic 
Inhibitor of MMP-
2 activity 
Kahweol 
 
Anti-angiogenic 
Inhibitor of MMP-
2, uPA activity and 
VEGF 
Leflunomide 
 
Anti-angiogenic 
Inhibitor of 
polymerization of 
β-tubulin 
Metformin 
 
Anti-tumoral 
Inhibitor of TOR 
pathway 
Paclitaxel 
 
Anti-tumoral 
Inhibitor of the 
polymerization of 
β-tubulin 
Sunitinib 
 
Anti-tumoral 
Inhibitor of 
tyrosine kinases 
TNP-470 
 
Anti-angiogenic 
Stimulating the 
production of cyclin-
dependent kinase 
inhibitor p21 and 
inactive methionine 
aminopeptidase-2 
Table 1. Names, structures and molecular targets of the compounds tested in 
this study.  
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Table 2. Effect of exposure schedule of EGCG on the 10 
tested compounds and sensitization on HMEC endothelial 
cells. IC50 values are given as means±SD of three 
independent experiments.  
 
 
Table 3. Effect of exposure schedule of EGCG on the 10 
tested compounds and sensitization on MDA-MB231 tumor 
cells. IC50 values are given as means±SD of three 
independent experiments.  
 
 
 
 
 4-MU DMF HT Kahweol Leflunomide 
EGCG 
(μM) 
IC50 (μM) 
Sensitization 
factor 
 IC50 (μM) 
Sensitization 
factor 
IC50 (μM) 
Sensitization 
factor 
IC50 (μM) 
Sensitization 
factor 
IC50 (μM) 
Sensitization 
factor 
0 626.7 ± 204.9 -  66.0 ± 2.4 - 78.6 ± 8.5 - 37.2 ± 2.9 - 210.8 ± 8.7 - 
5.6 876.9 ± 2.9 0.7  88.1 ± 5.8 0.7 208.0 ± 3.9 0.4 > 148.6   < 0.2 87.4 ± 40.1 2.4 
11.3 946.9 ± 146.6 0.7  60.3 ± 19.2 1.1 222.0 ± 2.5 0.4 74.4 ± 3.8 0.4 225.1 ± 70.6 0.9 
22.5 < 78.3   > 8.0  50.5 ± 7.9 1.3 193.1 ± 6.5 0.4 < 4.6   > 8.1 290.2 ± 47.7 0.7 
45 < 78.3   > 8.0  10.8 ± 3.6 6.1 10.1 ± 1.6  7.8 < 4.6 > 8.1 250.1 ± 15.3 0.8 
90 < 78.3   > 8.0  < 8.3   > 7.0 < 9.8   > 8.0 < 4.6 > 8.1 223.0 ± 18.2 0.9 
180 < 78.3   > 8.0  < 8.3   > 7.0 < 9.8 > 8.0 < 4.6 > 8.1 55.3 ± 11.7  3.8 
 Metformin Paclitaxel Sunitinib TNP-470 Vit. D3 
EGCG 
(μM) 
IC50 (μM) 
Sensitization 
factor 
 IC50 (μM) 
Sensitization 
factor 
IC50 (μM) 
Sensitization 
factor 
IC50 (μM) 
Sensitization 
factor 
IC50 (μM) 
Sensitization 
factor 
0 186.8 ± 8.7 -  1.1 ± 0.2 - 10.5 ± 1.2 - 8.5 ± 1.3 - 33.7 ± 3.0 - 
5.6 > 747.0   < 0.2  > 4.6   < 0.2 8.1 ± 2.6 1.3 15.0 ± 7.2 0.6 > 174.8   < 0.2 
11.3 > 747.0   < 0.2  > 4.6   < 0.2 13.8 ± 4.3 0.8 12.0 ± 3.1 0.7 > 174.8   < 0.2 
22.5 > 747.0   < 0.2  > 4.6   < 0.2 6.7 ± 0.8 1.5 7.4 ± 3.3 1.1 > 174.8   < 0.2 
45 > 747.0   < 0.2  2.2 ± 1.9 0.5 < 1.3   > 8.1 < 1.1   > 7.7 > 174.8   < 0.2 
90 58.0 ± 3.2 3.2  < 0.1   > 11 < 1.3 > 8.1 < 1.1 > 7.7 > 174.8   < 0.2 
180 < 23.3   > 8.0  < 0.1   > 11 < 1.3 > 8.1 < 1.1 > 7.7 > 5.5  < 6.1 
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Table 4. Combination index (CI) at IC50 of EGCG combined with each of the 10 
tested compounds in this study. Mean values are provided.  
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EGCG 
(HMEC) 
0.75 1.13 2.00 2.71 2.00 3.0 0.77 1.50 3.60 2.30 
EGCG 
(MDA-MB231) 
0.88 2.45 1.13 2.13 1.25 1.25 2.55 1.38 1.11 > 4 



